VYNE shares surge 19.88% after-hours on merger with Yarrow Bioscience and $200M financing.

VYNE Therapeutics Inc. surged 19.88% in after-hours trading following the announcement of its merger with private biotech company Yarrow Bioscience. The transaction, expected to close in Q2 2026, creates a combined entity focused on autoimmune thyroid diseases, trading under "YARW" on Nasdaq. A syndicate of healthcare investors, including RTW Investments and OrbiMed Advisors, committed $200 million in pre-closing financing, signaling strong investor confidence in the merged entity’s clinical-stage pipeline, particularly YB-101, a treatment targeting thyroid-stimulating autoantibodies. The merger aligns with VYNE’s strategy to expand into high-potential therapeutic areas, bolstered by recent licensing agreements and institutional backing. The after-hours rally reflects optimism around the strategic and financial benefits of the deal, positioning the combined company for enhanced R&D capabilities and market access.